http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
화상 환자에서 발생한 외과적 중재술을 요하는 감염성 심내막염 2예
김근숙,이태유,정연손,최창순,최민호,류제헌,김철홍,조구영,우흥정 대한감염학회 2003 감염과 화학요법 Vol.35 No.3
감염성 심내막염은 화상 후에 발생할 수 있는 치명적인 합병증이다. 임상 증상은 일반적으로 없는 경우가 대부분이고 지속되는 발열과 양성 혈액 배양 검사가 유일하다. 감염의 다른 확실한 원인 없이 발열과 양성 혈액 배양 검사가 있을 때는 감염성 심내막염을 강력하게 의심해야 하며 심장 초음파로 진단 가능하다. 감염성 심내막염은 사망률은 높지만 초기에 진단하면 항생제 정주를 지속하는 것으로 치료할 수 있다. 저자들은 화상환자에서 발생한 수술적 처치를 필요로 하는 감염성 심내막염 2예를 경험하였기에 보고하는 바이다. Infective endocarditis is a rare but fatal complication following burn injury. The clinical presentation is silent, but with persistent fever and positive blood culture. The manipulation of clinical care as well as the burn wound itself and immunosuppression caused by extensive bums puts the burn patients at risk of bacteremia. Staphylococcus aureus and Gram-negative bacilli are most common pathogens of infective endocarditis following burns. We report herein two cases of infective endocarditis in the burn patients who requires surgical intervention. The first case was caused by Pseudomonas aeruginosa with complication of multifocal pneumonia, and the second case by coagulase-negative stapylococcus with cerebral hemorrhage.
( Moon Hee Lee ),( Jong-hwa Jang ),( Gun Young Yoon ),( Seung Jun Lee ),( Min-goo Lee ),( Tae Heung Kang ),( Hee Dong Han ),( Hyuk Soon Kim ),( Wahn Soo Choi ),( Won Sun Park ),( Yeong-min Park ),( In 생화학분자생물학회(구 한국생화학분자생물학회) 2017 BMB Reports Vol.50 No.5
β-Agarase cleaves the β-1,4 linkages of agar to produce neoagarooligosaccharides (NAO), which are associated with various physiological functions. However, the immunological functions of NAO are still unclear. In this study, we demonstrated that β-agarase DagA-produced neoagarohexaose (DP6), an NAO product, promoted the maturation of dendritic cells (DCs) by Toll-like receptor 4 (TLR4). DP6 directly and indirectly enhanced the activation of natural killer (NK) cells in a TLR4-dependent manner in vitro and in vivo. Finally, the antitumor activity of DP6 against B16F1 melanoma cells was inhibited in NK cell-depletion systems by using NK-cell depleting antibodies in vivo. Collectively, the results indicated that DP6 augments antitumor immunity against B16F1 melanoma cells via the activation of DC-mediated NK cells in a TLR4-dependent manner. Thus, DP6 is a potential candidate adjuvant that acts as an immune cell modulator for the treatment of melanoma. [BMB Reports 2017; 50(5): 263-268]